S. Aureus Bacteremia
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (NCT01104662) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-04-19 |
Track S. Aureus Bacteremia automatically
Every clearance here is in the API, with alerts when new ones post.